The most innovative aspect of our work is the idea that the boundary between neighbouring genes is not fixed. We show that this boundary can be therapeutically reprogrammed with ASOs to create a fusion transcript that restores expression of a haploinsufficient neurodevelopmental gene. We have learned how to make these fusion transcripts functional. In this case, the induced Chaserr-Chd2 fusion RNA is not just an aberrant transcript, but is exported, translated, and produces functional CHD2 protein. That is a key part of the innovation.
Gene fusions are often thought of in the context of cancer, where transcriptional dysregulation or genomic rearrangements can generate oncogenic fusion proteins. Here, we are using a related biological principle in a very different way. Rather than allowing uncontrolled fusion events, we use ASOs to precisely reprogramme transcription between neighbouring genes and harness this process therapeutically. In effect, we are tricking the cell into boosting expression of a gene that is present but under-expressed, without needing to replace the entire gene.